A new study – the largest of its kind – has found that the Pfizer vaccine produces an “off the scale” immune response that is likely to protect against the Brazilian variant of COVID-19. The Telegraph has more.
The biggest study on antibody and cellular immune factors to date suggests people are likely to be protected against the Wuhan, Kent and Brazilian types of coronavirus following two doses of the vaccine.
The research, led by the University of Birmingham and including Public Health England’s Porton Down laboratory, found 98 per cent of people aged 80 or over who had two doses of the Pfizer jab had a strong antibody immune response.
Professor Paul Moss, from the University of Birmingham and leader of the UK Coronavirus Immunology Consortium, told a briefing: “We’ve certainly seen in this paper that the antibody levels are so good, really after the first two weeks, that we are pretty confident that this should be very helpful against the Brazilian variant.”
Worth reading in full.